Intersect Follows Leaders In ENT
Following the lead of ENT start-ups like Acclarent and Entellus Medical, Intersect ENT Inc. is introducing a line of stent like implants capable of performing the same role drug-eluting stents played in interventional cardiology. Intersect’s implants provide moderate structural support to tissue that has been cut or dilated through FESS or balloon sinuplasty. But the principal function of the implant isn’t propping open nasal passageways but rather delivering drugs. A trio of clinical studies conducted by the company has found the released steroids produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions.
You may also be interested in...
People Briefs: Owens & Minor, Laurimed, Xagenic, Intersect ENT
Owens & Minor launched a search to replace its retiring CEO; Laurimed named its new CEO; Xagenic hired a VP of product development; and Intersect ENT appointed a chief commercial officer.
Research Briefs: Data From Intersect ENT, BioVentrix and Hologic
Encouraging pilot trial results on a drug-eluting implant for sinusitis made by Intersect ENT. First-in-man procedure with myocardial anchoring system for heart failure from BioVentrix. Final analysis of registry data confirms the efficacy of Hologic’s MammoSite breast brachytherapy system.
Acclarent’s Balloon Sinuplasty Device Relieva Heads To Asian Clinics
Johnson & Johnson subsidiary Acclarent demonstrated its hand-held Relieva sinuplasty technology with its first in-office demonstration procedure in Malaysia, seeking to highlight the minimally invasive procedure for sinusitis as the company starts a push in Asia.